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Dexamethasone and radiation response in the Lewis lung
tumour model
0.0. Agboola*, J.A. Raleigh, J.E. Pedersen, R.C. Urtasun & G. Barron
Department ofRadiation Oncology, Cross Cancer Institute, Edmonton, Alberta T6G IZ2, Canada.
Dexamethasone is a synthetic steriod of widespread
use in oncology especially for the management of
radiation-induced cerebral oedema which
accompanies intracranial malignancies.It has been
recently suggested that Dexamethasone could
modify the severity and incidence of misonidazole
(MISO; 1-(2-hydroxy-3-methoxypropyl)-2-nitro-
imidazole) neurotoxicity (Walker & Strike, 1980;
Wasserman et al., 1980; Urtasun et al., 1982). Pros-
pective clinical studies are underway to assess the
efficacy of Dexamethasone when administered con-
comitantly with radiation and MISO (Urtasun et
al., 1982).
There is, however, recent published in vitro
evidence that overnight exposure to microgram
quantities of Dexamethasone decreases the
sensitivity of Chinese Hamster cells, V-79-753B to
radiation both in air and hypoxia (Millar & Jinks,
1981). This finding, if reproduced in animal tumour
systems could have an important impact on the
management of patients receiving radiation. We
therefore studied the effect of Dexamethasone on
the radiation response of Lewis lung tumour in
vivo.
Dexamethasone sodium phosphate solution
(Hexadrol) was obtained from Organon of Canada.
Dexamethasone phosphate is rapidly
dephosphorylated in vivo (Tsuei et al., 1979) and
for the purposes of serum and tissue analysis, an
authentic sample of the dephosphorylated
metabolite was purchased from Sigma Chemical
Company.
The Lewis lung tumour grown in the left
gastronemius.niuscle of C57 black mice was chosen
as the tumour model. It has shown consistent
growth and radiation response in C57/B1 mice in
our laboratory.
In order to demonstrate that sufficient levels of
Dexamethasone would be present in the tumour at
Correspondence: J.A. Raleigh
*Present Address: Radiotherapy Unit, University College
Hospital, Ibadan, Nigeria
Received March 16 1983; Accepted April 16 1983
B.J.C. E
the time of irradiation 6 x 106 tumour cells in
Waymouth's medium were injected s.c. into C57/B1
mice and when the tumour had obtained an average
diameter of 8mm, 50pgg- 1 body wt of
Dexamethasone phosphate was injected i.p. At
intervals following this injection mice were
sacrificed and blood withdrawn by intracardiac
puncture into a heparinized syringe. The
erythrocytes were spun down in a heparinized tube
at 2,000rpm for 15min. The plasma was drawn off
and stored in a plastic tube at 0°C. The tumour was
dissected out, placed in a plastic bottle, quickly
frozen in a dry ice 95% ethanol bath and stored at
- 80°C until analyzed.
The amount of Dexamethasone in the plasma
and tumour specimens was determined by a
modification of the high pressure liquid
chromatography (HPLC) method of Cham et al.
(1980). The procedure was modified in that
Dexamethasone was extracted from serum samples
or tumour homogenates by means of the SEP PAK
solid phase extraction system for steroids (Waters
Associates, Inc.). Weighed tumours were
homogenized in 1.5ml of distilled water in a Ten
Broeck homogenizer, the homogenates centrifuged
and the supernatants analyzed for Dexamethasone.
The accuracy of the measured levels of
Dexamethasone in tumour and serum is estimated
to be +15%.
In the radiation part of the experiment 4 groups
of C57/B1 mice bearing Lewis lung tumour in the
left gastronemius muscle were used. When the leg
diameter reached 8mm (0.25g of tumour) 12 mice
were placed in each of four groups (A to D): Group
A having no radiation, no Dexamethasone (Control
Group); Group B having Dexamethasone alone;
Group C having radiation alone; and Group D
having radiation and Dexamethasone.
Fifty pgg-1 body wt of Dexamethasone
phosphate was administered i.p. every 8h for 24h
(three doses) to Groups B and D; the last dose was
given 30min prior to radiation treatment in Group
D.
Irradiation (3,500 or 1000cGy (Theratron 60Co))
was given in a single dose to the tumour-bearing
legs of mice in Groups C and D. All the mice were
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irradiated at the same time in a jig constructed to
hold 24 unanaesthetized mice. The bodies of the
mice were protected from the direct beam of
radiation by 10 half-value layer thick lead (11 cm)
with the tumour-bearing legs only exposed to the
beam. To prevent lung metastases, all mice in
groups A to D had prophylactic radiation which
consisted of a 1,000 cGy single dose to the lungs
given 7 days after the inoculation of the legs with
tumour cells.
Measurement of the tumour size in the legs was
made every 2 days following tumour cell
inoculation up to 23 days after the radiation.
Tumour regrowth to 4 times the treatment size was
considered the experimental termination point.
The data were analyzed by means of a computer
programme which provided the average normalized
tumour volume for each group of tumours at each
measurement. The derived tumour volumes were
used to construct the leg volumes/time curve from
which the tumour growth delay in days as a
function of radiation dose was derived (Figure 1).
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Figure 1 Tumour regrowth delay for irradiated Lewis
lung tumours (mean of 12 mice per group plotted).
Untreated control (x); dexamethasone (@); 35Gy
(AL); 35Gy+dexamethasone (A); 10Gy (O);
10Gy+dexamethasone (U).
The concentration of Dexamethasone at 30min
after injection was found to reach a level of 23
±3.5pgg-' in the tumour and a comparable level
in the serum. At 8h the tumour level was
approximately 16pgg-' while the serum level had
fallen to 2ygml-'. It is clear that adequate levels of
Dexamethasone were present in the Lewis lung
tumours at the time of irradiation under the
conditions of the radiation experiment. The
persistence of Dexamethasone in the tumours of the
C57/B1 mice is consistent with the observation that
the plasma half-life of Dexamethasone in man is
-3h while tissue half-life is much longer ranging
from 36-72h (Tsuei et al., 1979; Swartz & Dluhy,
1978).
The log average tumour volume/time curve
(Figure 1) does not show any significant difference
in radiation response between the group that had
Dexamethasone and the group which was not given
the drug (i.e. Groups C and D). Also, no difference
was noted in the rate of tumour regrowth in the
control group (Group A) and the group given
Dexamethasone alone (Group B).
The usual dose of Dexamethasone prescribed in
the management of radiation-induced cerebral
oedema is in the range of 20mg per day in divided
doses. In our series of experiments, 50Mgg'- body
wt was given to each mouse (equivalent to 3.5g for
an average man weighing 70kg). We have found no
effect on the response of the Lewis lung tumour to
radiation in vivo. Our results are consistent with the
finding that Dexamethasone does not change the
radiation response of the CFU-S component of
bone marrow cells in vivo (Millar & Jinks, 1981).
On exposure V-79-753B Chinese Hamster cells
to the same concentration of Dexamethasone
(50pgml-1) over 24h, a considerable increase in Do
value was noted both in air and hypoxia (Millar &
Jinks, 1981). This find has raised concerns about
the well-established use of Dexamethasone in
clinical radiotherapy, particularly in the treatment
of CNS tumours. The possible radioprotection of
tumour cells is not substantiated in the results
obtained with our single mouse tumour model,
which should be extended by others using different
in vivo tumour model systems. At this time,
therefore, we continue to advocate the use of
Dexamethasone in combination with radiation
when clinically indicated.
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